Adaptive Biotechnologies Corp
ADPT · XNASCIK 1478320fmd_1DMMETEVM5XK04WQ36MN36YCY4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 35 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 38 | 56 | 85 | 98 | 154 | 185 | 170 | 179 | 277 |
| Cost of revenue | 16 | 20 | 22 | 23 | 49 | 58 | 76 | 72 | 71 |
| Gross profit | 23 | 36 | 63 | 76 | 105 | 127 | 95 | 107 | 206 |
| Research and development | 32 | 39 | 71 | 116 | 142 | 142 | 122 | 103 | 94 |
| Selling, general and administrative | 33 | 45 | 69 | 111 | 170 | 184 | 173 | 158 | 167 |
| Operating income | (44) | (50) | (78) | (153) | (209) | (200) | (227) | (163) | (57) |
| Interest expense | – | – | – | – | – | 4 | 14 | 12 | 12 |
| Interest and investment income | 2 | 3 | 10 | 7 | 2 | 4 | 16 | 15 | 9 |
| Income before taxes | – | – | (69) | (146) | (207) | (200) | (225) | (160) | (59) |
| Income tax expense | – | – | 0 | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (69) | – | – | – | (225) | (160) | (59) |
| Net income | (43) | (46) | (69) | (146) | (207) | (200) | (225) | (159) | (59) |
| Net income to common shareholders | (43) | (46) | (70) | (146) | (207) | – | – | – | – |